Eli L. Diamond, MD, is a neuro-oncologist who specializes in the care of patients with Erdheim-Chester disease (ECD) and other histiocytosis, as well as brain tumors and neurologic complications of cancer. He did his neurology residency at the Massachusetts General Hospital and Brigham and Women’s Hospital and his neuro-oncology training at Memorial Sloan Kettering Cancer Center (MSK), where he is currently a staff neuro-oncologist. He conducts and has conducted several research studies for patients with ECD including the vemurafenib trial, the cobimetinib trial, a study looking for gene mutations in ECD tumors, a study to improve ECD biopsies, and a study about ECD and the brain. At MSK, he works with a large team across many disciplines to offer the highest quality medical care and supportive care for patients with ECD, as well as to better our understanding and treatment of ECD with collaborative research.
Dr. Diamond is also the co-founder of the global ECD Patient Registry that has been supported by the ECD Global Alliance. In addition to this major contribution, he co-leads the ECD Care Center Referral Network.
Contact information
Memorial Sloan-Kettering Cancer Center
